Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vericel (VCEL – Research Report) and keeping the price target at $60.00.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including Vericel’s strong growth momentum and strategic initiatives. The company reported a significant year-over-year increase in MACI revenue, driven by an expanding surgeon customer base and biopsy growth, with expectations of continued revenue growth in the upcoming quarters. The MACI Arthro segment is gaining traction, with a substantial number of trained surgeons, which is anticipated to contribute to revenue growth later in 2025 and beyond.
Additionally, Vericel’s burn care franchise is expected to rebound, with management projecting stronger performance in the second quarter of 2025. Despite a slight underperformance in Epicel revenues due to external factors, the company remains focused on increasing penetration and consistent use of NexoBrid. Financially, Vericel maintains a strong cash position, sufficient to support its operations, and has reiterated its revenue growth guidance for 2025, which aligns with the analyst’s positive outlook on the company’s future performance.
Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, ImmunoPrecise Antibodies, and IN8bio. According to TipRanks, Ramakanth has an average return of -0.1% and a 34.93% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $55.00 price target.